Femtobiomed Statistics

Total Valuation

Femtobiomed has a market cap or net worth of KRW 22.19 billion.

Market Cap	22.19B
Enterprise Value	n/a

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Femtobiomed has 8.54 million shares outstanding.

Current Share Class	8.54M
Shares Outstanding	8.54M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	47.10%
Owned by Institutions (%)	n/a
Float	4.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	56.91
PB Ratio	21.59
P/TBV Ratio	28.01
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 12.25

Current Ratio	12.25
Quick Ratio	6.32
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1,690.34

Financial Efficiency

Return on equity (ROE) is -74.10% and return on invested capital (ROIC) is -45.09%.

Return on Equity (ROE)	-74.10%
Return on Assets (ROA)	-41.65%
Return on Invested Capital (ROIC)	-45.09%
Return on Capital Employed (ROCE)	-108.13%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.22
Inventory Turnover	2.42

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -67.21% in the last 52 weeks. The beta is 0.67, so Femtobiomed's price volatility has been lower than the market average.

Beta (5Y)	0.67
52-Week Price Change	-67.21%
50-Day Moving Average	3,305.50
200-Day Moving Average	4,294.60
Relative Strength Index (RSI)	32.46
Average Volume (20 Days)	2,947

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Femtobiomed had revenue of KRW 389.96 million and -1.21 billion in losses. Loss per share was -876.00.

Revenue	389.96M
Gross Profit	119.08M
Operating Income	-1.20B
Pretax Income	-1.21B
Net Income	-1.21B
EBITDA	-1.08B
EBIT	-1.20B
Loss Per Share	-876.00

Full Income Statement

Balance Sheet

The company has 319.50 million in cash and n/a in debt, giving a net cash position of 319.50 million or 37.43 per share.

Cash & Cash Equivalents	319.50M
Total Debt	n/a
Net Cash	319.50M
Net Cash Per Share	37.43
Equity (Book Value)	1.03B
Book Value Per Share	656.78
Working Capital	686.85M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.10 billion and capital expenditures -134.72 million, giving a free cash flow of -1.23 billion.

Operating Cash Flow	-1.10B
Capital Expenditures	-134.72M
Free Cash Flow	-1.23B
FCF Per Share	-144.49

Full Cash Flow Statement

Margins

Gross Margin	30.54%
Operating Margin	-307.76%
Pretax Margin	-310.32%
Profit Margin	n/a
EBITDA Margin	-275.77%
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Femtobiomed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-5.45%
FCF Yield	-5.56%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 22, 2021. It was a forward split with a ratio of 1.5.

Last Split Date	Jul 22, 2021
Split Type	Forward
Split Ratio	1.5

Scores

Femtobiomed has an Altman Z-Score of -7.29 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.29
Piotroski F-Score	1